Bluebird bio news centers on the company's commercial-stage gene therapy business for severe genetic diseases and its completed acquisition by funds managed by Carlyle and SK Capital. The company developed and delivered FDA-approved therapies for sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy, with recurring updates tied to commercial delivery, manufacturing infrastructure, treatment-center support, payer partnerships, and patient access.
Company news also documents the transaction process that ended Bluebird bio's public listing, including tender-offer communications, merger-agreement amendments, capital-structure matters, governance actions, and the cessation of trading in its common stock after the acquisition closed.
bluebird bio, Inc. (Nasdaq: BLUE) will discuss its first quarter 2024 results and business updates on May 9 at 8:00 a.m. ET. The company will also participate in investor conferences on May 16 and June 12. Investors can access the live webcasts on bluebird bio's website.
bluebird bio, Inc. announced the completion of the first commercial cell collection for LYFGENIA gene therapy, a one-time treatment for sickle cell disease. LYFGENIA was FDA-approved in December 2023 and is the most extensively studied gene therapy for the disease. The cells were collected at Children’s National Hospital in Washington, DC, marking a significant milestone in the treatment of sickle cell disease.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.